Expertise in
7
conditions

Dr. Marcia R. Cruz-Correa

Gastroenterology
San Juan, PR 
Clinical Trials:Currently Recruiting for 2 Trials
Expertise in
7
conditions
San Juan, PR 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Marcia Cruz-Correa is a Gastroenterologist in San Juan, Puerto Rico. Dr. Cruz-Correa is highly rated in 7 conditions, according to our data. Her top areas of expertise are Familial Adenomatous Polyposis, Colorectal Cancer, Familial Colorectal Cancer, Colonoscopy, and Endoscopy.

Her clinical research consists of co-authoring 94 peer reviewed articles and participating in 18 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
University Of Puerto Rico School Of Medicine
Specialties
Gastroenterology
Licenses
Internal Medicine in PR
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
First Medical Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medical Card System
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
  • PPO
MMM Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Plan De Salud Menonita
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 3 Less Insurance Carriers -

Locations

San Juan, PR 00909

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

16 Clinical Trials

A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)
A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)
Enrollment Status: Recruiting
Publish Date: December 17, 2025
Intervention Type: Procedure, Biological, Drug
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 2
Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Enrollment Status: Recruiting
Publish Date: June 27, 2025
Intervention Type: Drug
Study Drug: APL-101
Study Phase: Phase 2
A Phase IIa, Placebo-Controlled, Randomized Study of Daily Obeticholic Acid (OCA) to Reduce Intestinal Polyp Burden in Familial Adenomatous Polyposis (FAP)
A Phase IIa, Placebo-Controlled, Randomized Study of Daily Obeticholic Acid (OCA) to Reduce Intestinal Polyp Burden in Familial Adenomatous Polyposis (FAP)
Enrollment Status: Suspended
Publish Date: December 17, 2025
Intervention Type: Biological, Drug, Procedure, Other
Study Drug: Obeticholic Acid
Study Phase: Phase 2
Phase I Trial of a Therapeutic DNA Vaccine for Chronic Hepatitis C Virus (HCV) Infection
Phase I Trial of a Therapeutic DNA Vaccine for Chronic Hepatitis C Virus (HCV) Infection
Enrollment Status: Active_not_recruiting
Publish Date: December 17, 2025
Intervention Type: Other, Biological
Study Drugs: Electroporation-Mediated Plasmid DNA Vaccine Therapy, HCV DNA Vaccine INO-8000, Rocakinogene Sifuplasmid
Study Phase: Phase 1
A Phase IIB Clinical Trial of the Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury) Vaccines (TRI-AD5) and IL-15 Superagonist N-803 in Lynch Syndrome
A Phase IIB Clinical Trial of the Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury) Vaccines (TRI-AD5) and IL-15 Superagonist N-803 in Lynch Syndrome
Enrollment Status: Active_not_recruiting
Publish Date: December 01, 2025
Intervention Type: Procedure, Drug, Other, Biological
Study Phase: Phase 2
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 3
A Phase Ib/II Clinical Trial of Nous-209 for Recurrent Neoantigen Immunogenicity and Cancer Immune Interception in Lynch Syndrome
A Phase Ib/II Clinical Trial of Nous-209 for Recurrent Neoantigen Immunogenicity and Cancer Immune Interception in Lynch Syndrome
Enrollment Status: Active_not_recruiting
Publish Date: October 17, 2025
Intervention Type: Procedure, Biological, Other
Study Drugs: Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP, MVA Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP
Study Phase: Phase 1/Phase 2
Statin Therapy to Reduce Disease Progression From Liver Cirrhosis to Cancer
Statin Therapy to Reduce Disease Progression From Liver Cirrhosis to Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 17, 2025
Intervention Type: Procedure, Other, Drug
Study Drug: Simvastatin
Study Phase: Phase 2
Randomized, Double-Blind, Placebo-Controlled Trial of Meriva® (Curcuminoids) as a Candidate Chemoprevention Agent for Gastric Carcinogenesis
Randomized, Double-Blind, Placebo-Controlled Trial of Meriva® (Curcuminoids) as a Candidate Chemoprevention Agent for Gastric Carcinogenesis
Enrollment Status: Active_not_recruiting
Publish Date: September 15, 2025
Intervention Type: Other, Drug
Study Drug: Curcumin
Study Phase: Phase 2
A Phase II Study of Checkpoint Blockade Immunotherapy in Patients With Somatically Hypermutated Recurrent WHO Grade 4 Glioma
A Phase II Study of Checkpoint Blockade Immunotherapy in Patients With Somatically Hypermutated Recurrent WHO Grade 4 Glioma
Enrollment Status: Active_not_recruiting
Publish Date: September 09, 2025
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Study Comparing the Efficacy and Safety of Tislelizumab (BGB-A317) Plus Platinum and Fluoropyrimidine Versus Placebo Plus Platinum and Fluoropyrimidine as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Study Comparing the Efficacy and Safety of Tislelizumab (BGB-A317) Plus Platinum and Fluoropyrimidine Versus Placebo Plus Platinum and Fluoropyrimidine as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Enrollment Status: Completed
Publish Date: February 14, 2025
Intervention Type: Drug
Study Phase: Phase 3
Increasing Socioeconomically Disadvantaged Patients' Engagement in Breast Cancer Surgery Decision Making Through a Shared Decision Making Intervention
Increasing Socioeconomically Disadvantaged Patients' Engagement in Breast Cancer Surgery Decision Making Through a Shared Decision Making Intervention
Enrollment Status: Active_not_recruiting
Publish Date: January 28, 2025
Intervention Type: Other
Study Phase: Not Applicable
Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other, Dietary supplement, Drug
Study Drugs: Bevacizumab, Oxaliplatin, Leucovorin calcium, Fluorouracil, Irinotecan hydrochloride, Irinotecan
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
Enrollment Status: Completed
Publish Date: December 27, 2024
Intervention Type: Drug
Study Drugs: Mirikizumab, Ustekinumab
Study Phase: Phase 3
A Phase I Single-arm, Multicenter Pilot Study Aimed at Validating γ-OHPdG as a Biomarker and Testing the Effects of Polyphenon E on Its Levels in Patients With Cirrhosis
A Phase I Single-arm, Multicenter Pilot Study Aimed at Validating γ-OHPdG as a Biomarker and Testing the Effects of Polyphenon E on Its Levels in Patients With Cirrhosis
Enrollment Status: Active_not_recruiting
Publish Date: August 02, 2024
Intervention Type: Procedure, Drug, Other
Study Drug: Defined Green Tea Catechin Extract
Study Phase: Phase 1
Phase II Trial of Weekly Erlotinib Dosing to Reduce Duodenal Polyp Burden Associated With Familial Adenomatous Polyposis
Phase II Trial of Weekly Erlotinib Dosing to Reduce Duodenal Polyp Burden Associated With Familial Adenomatous Polyposis
Enrollment Status: Completed
Publish Date: July 26, 2022
Intervention Type: Drug
Study Drug: Erlotinib
Study Phase: Phase 2
View 14 Less Clinical Trials

94 Total Publications

Tislelizumab + Chemotherapy in Gastric Cancer: Long-Term RATIONALE-305 Randomized Trial Follow-up.
Tislelizumab + Chemotherapy in Gastric Cancer: Long-Term RATIONALE-305 Randomized Trial Follow-up.
Journal: Advances in therapy
Published: August 13, 2025
Similar Doctors
Expertise in
3
conditions
Dr. Jorge L. Cortes
Gastroenterology
Expertise in
3
conditions
Dr. Jorge L. Cortes
Gastroenterology
502 Instituto San Pablo, 
Bayamon, PR 
 (6.7 miles away)
787-778-0632
Languages Spoken:
English
See accepted insurances

Jorge Cortes is a Gastroenterologist in Bayamon, Puerto Rico. Dr. Cortes is highly rated in 3 conditions, according to our data. His top areas of expertise are Diverticular Disease, Gastric Dysmotility, Chronic Erosive Gastritis, Gastrostomy, and Gastrectomy.

Expertise in
8
conditions
Dr. Alvaro Reymunde-Posso
Gastroenterology
Expertise in
8
conditions
Dr. Alvaro Reymunde-Posso
Gastroenterology
2225 Ponce Byp, Suite 806, 
Ponce, PR 
 (46.8 miles away)
Languages Spoken:
English
See accepted insurances

Alvaro Reymunde-Posso is a Gastroenterologist in Ponce, Puerto Rico. Dr. Reymunde-Posso is highly rated in 8 conditions, according to our data. His top areas of expertise are Gastric Dysmotility, Gastritis, Chronic Erosive Gastritis, and Diverticular Disease.

Expertise in
3
conditions
Dr. Vasco Eguia-Moreda
Gastroenterology
Expertise in
3
conditions
Dr. Vasco Eguia-Moreda
Gastroenterology
1607 Ave Ponce De Leon, 
San Juan, PR 
 (0.1 miles away)
787-910-0909
Languages Spoken:
English
See accepted insurances

Vasco Eguia-Moreda is a Gastroenterologist in San Juan, Puerto Rico. Dr. Eguia-Moreda is highly rated in 3 conditions, according to our data. His top areas of expertise are Esophageal Cancer, Insulinoma, Glucagonoma, Stomach Cancer, and Gastrostomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Cruz-Correa's expertise for a condition
ConditionClose
View All 8 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile